Evidence map›Paper›PMID 40735485›Full record

ArticleFrontiers in pharmacology2025

Fucoxanthin inhibits the proliferation of MOLM13 cells by targeting AKT to disrupt glucose metabolism.

Tingting Niu, Ying Chen, Mengmeng Sun, Cong Shi, Duobing Zou, Wei Wu, Yuzhan Chen, Juanjuan Chen, Haimin Chen, Guifang Ouyang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tingting Niu *Laboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Ying Chen *Laboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Mengmeng SunLaboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Cong ShiLaboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Duobing ZouLaboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Wei WuCollaborative Innovation Center for Zhejiang Marine High-efficiency and Healthy Aquaculture, Ningbo University, Ningbo, Zhejiang, China.
Yuzhan ChenLaboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Juanjuan ChenCollaborative Innovation Center for Zhejiang Marine High-efficiency and Healthy Aquaculture, Ningbo University, Ningbo, Zhejiang, China.
Haimin ChenCollaborative Innovation Center for Zhejiang Marine High-efficiency and Healthy Aquaculture, Ningbo University, Ningbo, Zhejiang, China.
Guifang OuyangDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Qitian MuLaboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fucoxanthin is a natural carotenoid that has remarkable anti-tumor effects and an excellent safety profile. Here, we combined molecular docking, dynamics simulations, and functional assays (CCK-8, flow cytometry, glucose/ATP detection) to decipher the mechanism of Fucoxanthin on FLT3-ITD AML cells. Fucoxanthin (25 μM) reduced MOLM13 (FLT3-ITD) cell viability by 63.6% (

Indexed as

acute myeloid leukemiaAktfucoxanthinglucose metabolismGLUT1

Identifiers

PMID40735485
PMCPMC12303925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.